CAR-T cell activation is crucial for the success of CAR-T cell therapy as it allows the engineered T cells to effectively recognize, target, and eliminate cancer cells. In this webinar, our two panelists will discuss a streamlined workflow to engineer and characterize CAR-T cell signaling and activation status, revealing the kinetics of CAR-T cell activation and signal transduction with reproducible quantification.

The speakers will first discuss how they leveraged Bio-Techne’s non-viral gene editing TcBuster™ platform to edit human primary T cells with a CD19 CAR. After CAR activation, they then utilized a first-to-market anti-CAR linker antibody from Cell Signaling Technology (CST) to identify and confirm CAR expression, regardless of CAR antigen specificity. Finally, they will review the implementation of automated protein analytical solutions to characterize cytokine secretion using Simple Plex™ on the microfluidic ELISA Ella™ platform and intracellular signaling events using the capillary immunoassay Simple Western™ platform with high-quality signaling antibodies from CST.

You will learn about:

• How Simple Western and Simple Plex immunoassay platforms provide granular time course information on CAR-T cell signaling and activation using just a few microliters of sample with hands-free automation
• How anti-CAR linker antibodies can be used to confirm CAR expression, regardless of CAR antigen specificity, using both flow cytometry and capillary immunoassay read-outs 
• How Simple Western platform reveals detailed kinetics of CAR trafficking and intracellular CAR-T cell signaling events with reproducible quantitation
• How Simple Plex platform characterizes CAR-T cell activation with simultaneous quantification of 4 secreted cytokines in a single 90-minute run

• Immune cell therapy researchers
• CAR-T cell therapy researchers
• Cell biologists